Fig. 2From: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancerCSC evaluation in core biopsy samples by flow cytometry. a ALDH+ cells. b CD24−/CD44+ cells. Symbols represent individual patients. Patient 16’s day 21 core biopsy was taken on the day of surgeryBack to article page